Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 7/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10947183 | 1.00 | TSHR (0.47) | TSHRTHRBHSD17B10CES2CTSL | |
| SCHEMBL10945827 | 1.00 | TSHR (0.47) | TSHRTHRBHSD17B10CES2CTSL | |
| SCHEMBL20638555 | 1.00 | TSHR (0.47) | TSHRTHRBHSD17B10CES2CTSL | |
| SCHEMBL10948179 | 1.00 | TSHR (0.47) | TSHRTHRBHSD17B10CES2CTSL | |
| SCHEMBL16710770 | 1.00 | TSHR (0.47) | TSHRTHRBHSD17B10CES2CTSL | |
| SCHEMBL10943824 | 1.00 | TSHR (0.47) | TSHRTHRBHSD17B10CES2CTSL | |
| SCHEMBL3380001 | 0.97 | — | — | |
| SCHEMBL1220054 | 0.91 | TSHR (0.57) | TSHRTHRBHSD17B10CES2CTSL | |
| SCHEMBL10943798 | 0.91 | — | — | |
| SCHEMBL9330272 | 0.91 | TSHR (0.57) | TSHRTHRBHSD17B10CES2CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360179-A1 | STAPLED PEPTIDES AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2024-10-31 | — | — | US | disclosed |
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2024-04-11 | — | — | US | disclosed |
| EP-3301177-A1 | RNAI AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES | Alnylam Pharmaceuticals, Inc. (US) | 2018-04-04 | — | — | EP | disclosed |
| US-20160333277-A1 | METHOD FOR REMOVING SULFUR COMPOUNDS FROM HYDROCARBON STREAMS | BASF SE (DE) | 2016-11-17 | — | — | US | disclosed |
| EP-3092288-A1 | METHOD FOR REMOVING SULFUR COMPOUNDS FROM HYDROCARBON STREAMS | BASF SE (DE) | 2016-11-16 | — | — | EP | disclosed |
| CN-106103665-A | Process for removing sulfur compounds from a hydrocarbon-containing stream | 巴斯夫欧洲公司 | 2016-11-09 | — | — | CN | disclosed |
| WO-2015188197-A2 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | SOLSTICE BIOLOGICS, LTD. (IE) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015104304-A1 | METHOD FOR REMOVING SULFUR COMPOUNDS FROM HYDROCARBON STREAMS | BASF SE (DE) | 2015-07-16 | — | — | WO | disclosed |
| WO-2015069932-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING DISULFIDE GROUPS | SOLSTICE BIOLOGICS, LTD. (IE) | 2015-05-14 | — | — | WO | disclosed |
| CN-101253256-B | Method for desulfurization of hydrocarbon oil | JAPAN ENERGY CORP | 2011-11-16 | — | — | CN | disclosed |
| US-20100155303-A1 | METHOD FOR DESULFURIZATION OF HYDROCARBON OIL | JAPAN ENERGY CORPORATION (JP) | 2010-06-24 | — | — | US | disclosed |
| CN-101253256-A | Method for desulfurization of hydrocarbon oil | JAPAN ENERGY CORP (JP) | 2008-08-27 | — | — | CN | disclosed |
| EP-1923451-A1 | METHOD FOR DESULFURIZATION OF HYDROCARBON OIL | JAPAN ENERGY CORPORATION (JP) | 2008-05-21 | — | — | EP | disclosed |
| US-7365055-B2 | Derivatives of morphine-6-glucuronide, pharmaceutical compositions containing them, their preparation method and their uses | BTG INTERNATIONAL LIMITED (GB) | 2008-04-29 | — | — | US | disclosed |
| US-3957745-A | FLAVORING AND FRAGRANCE COMPOSITIONS | UNIVERSAL OIL PRODUCTS COMPANY (US) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | CTNNB1, APC, CTNNA1 | TSHR 3955/4885THRB 2824/4885HSD17B10 4559/4885 |
| US-20240360179-A1 | STAPLED PEPTIDES AND METHODS THEREOF | CTNNB1, APC, CTNNA1 | TSHR 4247/4885THRB 2941/4885HSD17B10 4527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.